9926:HKEXAkeso, Inc. Analysis

Akeso, Inc. is trading well below its 20‑day (≈97) and 50‑day (≈98) SMAs, placing the stock in a bearish price zone despite a modestly bullish MACD crossover (line above signal) and an RSI hovering in the mid‑40s. Volatility is extreme at roughly 77% over the past 30 days, volume is on a decreasing trend, and the beta of ~0.8 suggests the share moves less than the market but with heightened price swings. The technical picture is reinforced by a support level near 87.5 HKD, resistance around 108 HKD, and an upside‑downside model that flags an 82% upside potential, while the Fear‑Greed Index reads “Extreme Greed.”
Fundamentally, revenue surged 50% year‑over‑year and gross margins sit at an impressive 77%, yet operating margins are deeply negative and cash flow remains in the red. The balance sheet is cash‑rich (≈9.2 bn HKD) but carries ~4.6 bn HKD of debt, yielding a debt‑to‑equity near 51%. Forward EPS is projected positive, driving a forward P/E of ~46 versus an industry average of ~30, and analysts (20 in count) rate the stock as a strong buy with median price targets around 166 HKD. The combination of a high valuation, substantial upside expectations, and a pipeline of bi‑specific antibodies creates a growth‑oriented but risk‑laden investment case.